- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Legend Biotech Corp (LEGN)
Legend Biotech Corp stock price live, this page displays NASDAQ LEGN stock exchange data. View the LEGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Legend Biotech Corp real time stock price chart below.
What Is the Legend Biotech Corp Stock Price Today?
The Legend Biotech Corp stock price today is 37.20.
What Is the Stock Symbol for Legend Biotech Corp?
The stock symbol for Legend Biotech Corp is "LEGN."
What Stock Exchange Does Legend Biotech Corp Trade On?
Legend Biotech Corp is listed and trades on the NASDAQ stock exchange.
Is Legend Biotech Corp a Good Stock to Buy?
Determining whether Legend Biotech Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LEGN quote. (ISIN: US52490G1022)
What Is the Legend Biotech Corp Stock Price Today?
The Legend Biotech Corp stock price today is 37.20.
What Is the Stock Symbol for Legend Biotech Corp?
The stock symbol for Legend Biotech Corp is "LEGN."
What Stock Exchange Does Legend Biotech Corp Trade On?
Legend Biotech Corp is listed and trades on the NASDAQ stock exchange.
Is Legend Biotech Corp a Good Stock to Buy?
Determining whether Legend Biotech Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LEGN quote. (ISIN: US52490G1022)
37.20
-0.85(-2.23%)
Closed
After Hours
37.15-0.05(-0.13%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
36.45
38.71
52 wk Range
30.17
65.45
LEGN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
36.4538.71
52 wk Range
30.1765.45
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LEGN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Price Target
78.01
Upside
+109.71%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings upwards for the upcoming period
Legend Bio Company Profile
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate, ciltacabtagene autoleucel, or cilta-cel, is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, and a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
Legend Biotech Corp SWOT Analysis
Carvykti's Triumph | Legend Biotech's CAR-T therapy for multiple myeloma shows strong sales growth, exceeding estimates with potential peak sales of $5-10 billion |
Manufacturing Mastery | Explore Legend's ambitious plans to double supply capacity by 2025, aiming for 10,000 treatment slots amid impressive revenue growth |
Market Dynamics | Delve into Legend's competitive edge in the multiple myeloma market, bolstered by its partnership with Johnson & Johnson |
Future Horizons | Analysts project continued growth with price targets ranging from $73 to $94, despite near-term challenges and potential M&A speculation |
Legend Biotech Corp Earnings Call Summary for Q4/2024
- CARVICTI sales surged 110% YoY to $334M, driving total Q4 revenue to $187M with $26M net profit ($0.07 EPS)
- Legend Biotech targets operational breakeven for CARVICTI by end-2025, company-wide profitability by 2026
- Plans to expand patient capacity to 10,000 by end-2025, investing $150M in Techland facility
- Stock rose 2.26% premarket to $34.80; company ended year with $1.1B cash and equivalents
- Maintains 90% market share in multiple myeloma CAR T therapy, expanding outpatient and community oncology presence
Last Updated: 11-03-2025, 07:00 pm
Read Full TranscriptCompare LEGN to Peers and Sector
Metrics to compare | LEGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLEGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −38.6x | −0.4x | −0.5x | |
PEG Ratio | −0.58 | 0.00 | 0.00 | |
Price/Book | 6.6x | 0.5x | 2.6x | |
Price / LTM Sales | 10.9x | 13.7x | 3.0x | |
Upside (Analyst Target) | 109.7% | 189.3% | 56.6% | |
Fair Value Upside | Unlock | 27.1% | 10.1% | Unlock |
Analyst Ratings
21 Buy
2 Hold
0 Sell
Ratings:
23 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 78.01
(+109.71% Upside)
Earnings
Latest Release
Mar 11, 2025
EPS / Forecast
-0.16 / -0.25
Revenue / Forecast
186.52M / 173.99M
FAQ
What Is the Legend Bio (LEGN) Stock Price Today?
The Legend Bio stock price today is 37.20.
What Stock Exchange Does Legend Bio Trade On?
Legend Bio is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Legend Bio?
The stock symbol for Legend Bio is "LEGN."
What Is the Legend Bio Market Cap?
As of today, Legend Bio market cap is 6.83B.
What is Legend Bio Earnings Per Share?
The Legend Bio EPS is -0.968.
What Is the Next Legend Bio Earnings Date?
Legend Bio will release its next earnings report on 13 May 2025.
From a Technical Analysis Perspective, Is LEGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.